Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.35 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.35 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8912082 | 0.86 | KDM4E (0.38) | KDM4ELMNAKMT2AMEN1CYP2D6 | |
| SCHEMBL9238656 | 0.83 | KDM4E (0.44) | KDM4EKMT2AMEN1CYP2D6 | |
| SCHEMBL6321358 | 0.82 | KDM4E (0.37) | KDM4EKMT2AMEN1CYP2D6MAPT | |
| SCHEMBL20768154 | 0.77 | KMT2A (0.38) | KDM4EKMT2AMEN1CYP2D6 | |
| SCHEMBL6698149 | 0.76 | KMT2A (0.34) | KDM4EKMT2AMEN1CYP2D6 | |
| SCHEMBL8188378 | 0.73 | KMT2A (0.46) | KMT2AMEN1CYP2D6 | |
| SCHEMBL7246865 | 0.72 | KDM4E (0.39) | KDM4ELMNACYP2D6GRIN1GRIN2A | |
| SCHEMBL8806580 | 0.71 | KMT2A (0.44) | LMNAKMT2AMEN1MAPT | |
| SCHEMBL392779 | 0.71 | CYP11B1 (0.43) | LMNAKMT2AMEN1CYP2D6MAPT | |
| SCHEMBL7672726 | 0.71 | MAPT (0.67) | KDM4ELMNAKMT2ACYP2D6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0904275-B1 | PREPARATION OF PHOSPHOROTHIOATE OLIGOMERS | UNIV MCGILL (CA) | 2006-05-17 | — | — | EP | disclosed |
| US-6861518-B2 | Hybrid oligonucleotide | MCGILL UNIVERSITY (CA) | 2005-03-01 | — | — | US | disclosed |
| US-20040097722-A9 | Preparation of phosphorothioate oligomers | MCGILL UNIVERSITY | 2004-05-20 | — | — | US | disclosed |
| US-20030229219-A1 | Preparation of phosphorothioate oligomers | ISIS PHARMACEUTICALS, INC. | 2003-12-11 | — | — | US | disclosed |
| US-6596857-B1 | Oligomer for use as tool in human diagnostics and therapeutics | MCGILL UNIVERSITY (CA) | 2003-07-22 | — | — | US | disclosed |
| US-20030114660-A1 | Preparation of phosphorothioate oligomers | JUST GEORGE (CA) | 2003-06-19 | — | — | US | disclosed |
| US-6476216-B1 | Preparation of phosphorothioate oligomers | MCGILL UNIVERSITY (CA) | 2002-11-05 | — | — | US | disclosed |
| US-6160109-A | Preparation of phosphorothioate and boranophosphate oligomers | ISIS PHARMACEUTICALS, INC. (US) | 2000-12-12 | — | — | US | disclosed |
| US-6031092-A | Preparation of phosphorothioate oligomers | MC GILL UNIVERSITY (CA) | 2000-02-29 | — | — | US | disclosed |
| WO-2000000499-A1 | METHOD FOR PREPARING OLIGONUCLEOTIDES WITH BORANOPHOSPHATE LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 2000-01-06 | — | — | WO | disclosed |
| US-5945521-A | Preparation of phosphorothioate oligomers | MCGILL UNIVERSITY (CA) | 1999-08-31 | — | — | US | disclosed |
| EP-0904275-A1 | PREPARATION OF PHOSPHOROTHIOATE OLIGOMERS | McGILL UNIVERSITY (CA) | 1999-03-31 | — | — | EP | disclosed |
| US-5734041-A | Preparation of chiral phosphorothioate oligomers | MCGILL UNIVERSITY (CA) | 1998-03-31 | — | — | US | disclosed |
| WO-1997014710-A1 | PREPARATION OF PHOSPHOROTHIOATE OLIGOMERS | MCGILL UNIVERSITY (US) | 1997-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114660-A1 | Preparation of phosphorothioate oligomers | RNGTT, NUDT1, OSGEP | KDM4E 4860/4885LMNA 1629/4885KMT2A 4098/4885 |
| US-20030229219-A1 | Preparation of phosphorothioate oligomers | RNGTT, NUDT1, OSGEP | KDM4E 4860/4885LMNA 1629/4885KMT2A 4098/4885 |
| US-20040097722-A9 | Preparation of phosphorothioate oligomers | RNGTT, NUDT1, OSGEP | KDM4E 4860/4885LMNA 1629/4885KMT2A 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.